Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT05864144 is registered in ClinicalTrials.gov with Sensei Biotherapeutics, Inc. as lead sponsor.

NCT NCT05864144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05864144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Lead sponsor
Sensei Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2023
Completion date
June 2, 2026
Enrollment
98 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, bladder cancer, breast cancer, cervix cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, melanoma, merkel cell carcinoma, metastatic cancer, non small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, refractory cancer, sarcoma, solid tumor, adult, thyroid cancer, uterine cancer